- Market Capitalization, $K 1,428,495
- Shares Outstanding, K 306,544
- Annual Sales, $ 2,212 M
- Annual Income, $ -129,990 K
- 60-Month Beta 1.26
- Price/Sales 0.65
- Price/Cash Flow 3.28
- Price/Book 9.26
|Period||Period Low||Period High||Performance|
| || |
+0.41 (+9.56%)since 11/03/23
| || |
+0.48 (+11.37%)since 09/01/23
| || |
+2.27 (+93.42%)since 12/02/22
Amneal: Q3 Earnings Snapshot
The pharmaceutical sector is expected to thrive due to the rising demand for advanced medicines to treat lifestyle diseases and its increasing ability to meet quality treatment needs thanks to technological...
Amneal: Q2 Earnings Snapshot
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such...
Stocks that traded heavily or had substantial price changes on Wednesday: MP Materials, Wolfspeed rise; Amneal, Knight-Swift fall
The company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.
Amneal: Q1 Earnings Snapshot
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023.
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|Amneal Pharmaceuticals Inc|
|GS Activebeta U.S. Small Cap Equity ETF|
|FTSE RAFI US 1500 Small/Mid Invesco ETF|
|Wellington Fund Vanguard ETF|
|Russell 2000 Value Ishares ETF|
|Russell 2000 Value Vanguard|